Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

In development
Reference number: GID-TA11774
Expected publication date: 30 September 2026

Documents

Documents created during the development process.

Invitation to participate

Final scope (PDF 123 KB)

Published:

28 October 2025
Final stakeholder list (PDF 136 KB)

Published:

28 October 2025
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 156 KB)

Published:

28 October 2025
Equality impact assessment (scoping) (PDF 103 KB)

Published:

28 October 2025

Notes

To appraise the clinical and cost effectiveness of Catumaxomab within its marketing authorisation for treating malignant ascites ID6580

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6580

Provisional stakeholder list post referral (PDF 153 KB)

Published:

25 July 2025
Draft scope post referral (PDF 150 KB)

Published:

25 July 2025